CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Project PREVAIL focuses on developing a new antibiotic, Laterocidamide, to combat antibiotic-resistant Gram-negative bacterial infections. This innovative drug aims to provide an effective treatment option against strains resistant to existing antibiotics, particularly polymyxins.
The emergence of Gram-negative bacterial resistance against antibiotics, especially the last-line-of-defense polymyxins, presents a societal threat with the potential to inflict higher healthcare costs and life-threatening patient risks.
For decades, physicians have relied on polymyxins as a last line of defense to treat resistant Gram-negative bacterial infections that do not respond to standard antibiotic therapies.
However, in 2016, a new polymyxin resistance mechanism surfaced: mobilized col…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
